4 reports

  • Zarour HM, et al. (2003). Categories of tumor antigens. Cancer Medicine; 6th Edition
  • KTE-C19 CAR ( KITE PHARMA, INC. - PIPELINE )

Global Cancer Immunotherapies Market to 2024 - Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline Summary Cancer immunotherapy, which can predominantly be classed as a form of targeted therapy, drives an immune response against cancer cells. This...

  • Cancer
  • Cancer Immunotherapy
  • Therapy
  • BioTherapeutics Inc.
  • Idera Pharmaceuticals, Inc.
  • Apr 18, 2017: Lion Biotechnologies Highlights Publication of New Translational Data in Science for TIL Therapy for Treatment of Cervical Cancer
  • Apr 18, 2017: Lion Biotechnologies Highlights Publication of New Translational Data in Science for TIL Therapy for Treatment of Cervical Cancer

Summary Iovance Biotherapeutics Inc (Iovance), formerly Lion Biotechnologies Inc is a biotechnology company that focuses on developing novel cancer immunotherapy products for treating various cancers.It develops products based on tumor-infiltrating lymphocyte (TIL) technology. The company’s lead product candidate,...

  • Biotechnology
  • Biotherapeutic
  • Cancer
  • Therapy
  • BioTherapeutics Inc.
  • SILLAJEN ENTERS INTO R&D AGREEMENT WITH NATIONAL CANCER INSTITUTE
  • REGENERON PHARMA AND SILLAJEN BIOTHERAPEUTICS ENTER INTO AGREEMENT

Summary Sillajen Biotherapeutics (SillaJen), formerly SillaJen Inc, is a biotechnology company that designs and develops oncolytic immunotherapeutics for the treatment of cancer.The company’s pipeline products comprise Pexa-Vec, an oncolytic immunotherapeutic virus which is in Phase III trial that is used for the treatment...

  • Biotherapeutic
  • Cancer
  • Healthcare
  • Pharmaceutical
  • BioTherapeutics Inc.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018 (CONTD..2), H1 2018

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.